Search
Search Results
##search.searchResults.foundPlural##
-
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3331PDF: 957HTML: 2968 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2185PDF: 1734HTML: 384 -
NUTRITIONALLY VARIANT STREPTOCOCCI BACTEREMIA IN CANCER PATIENTS: A RETROSPECTIVE STUDY, 1999-2014
2162PDF: 1021HTML: 4080Cover Letter: 226Figure 1: 238Figure 2: 235Table 1: 208 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
1918PDF: 731HTML: 2122Untitled: 225Untitled: 158Untitled: 177Untitled: 161Untitled: 171Untitled: 184Untitled: 192 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1079PDF: 1186Suppl. Files: 571HTML: 92 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3139PDF: 923HTML: 2072 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
823PDF: 99HTML: 148 -
DIAGNOSTIC VALUE OF BRONCHOALVEOLAR LAVAGE IN LEUKEMIC AND BONE MARROW TRANSPLANT PATIENTS: THE IMPACT OF ANTIMICROBIAL THERAPY
1994PDF: 829HTML: 2207Table 1: 184Table 2: 204Table 3: 198Table 4: 204Table 5: 198Tble 6: 191Cover Letter: 211Greene Tab.7: 202 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2913PDF: 862HTML: 6534Untitled: 242Untitled: 201Untitled: 218Untitled: 227 -
NF- ?B Essential Modulator Deficiency Leading to Disseminated Cutaneous Atypical Mycobacteria
1749PDF: 1112HTML: 10707Untitled: 196 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1212PDF: 850HTML: 3368 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2078PDF: 851HTML: 261 -
Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome – A Case Series and Review
3616PDF: 1520HTML: 4439CoverLetter: 189Figure1: 202 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1403PDF: 859HTML: 141 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2638PDF: 759HTML: 2315 -
INCREASE IN CANDIDA PARAPSILOSIS CANDIDEMIA IN CANCER PATIENTS
1810PDF: 1090HTML: 260 -
Bordetella Bronchiseptica in the Immunosuppressed Population – A Case Series and Review.
2522PDF: 1328HTML: 1799CoverLetter: 185 -
A Case of Rupioid Syphilis Masquerading as Aggressive Cutaneous Lymphoma
2284PDF: 1031HTML: 5078Cover Letter: 173Figure 2: 168Figure 1: 179Figure 3: 201Figure 4: 174Figure Legend: 190Table 1: 195Table 2: 187Table 3: 188 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1372PDF: 1253HTML: 463 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3611PDF: 2532HTML: 1508 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2655PDF: 1635HTML: 2375Table1: 196 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3705PDF: 908HTML: 6726 -
CROCIN PROMOTES APOPTOSIS IN HUMAN EBV-TRANSFORMED B-LYMPHOCYTE VIA INTRINSIC PATHWAY CROCIN PROMOTES APOPTOSIS IN EBV-TRANSFORMED LCL
1316PDF: 506HTML: 207 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1532PDF: 1091HTML: 225 -
Hsa-miR-5581-3p and hsa-miR-542-3p target the F8 gene in hemophilia A without F8 mutations F8 gene is regulated by miRNAs
1149PDF: 504HTML: 246 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4448PDF: 1735HTML: 1062 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2282PDF: 1065HTML: 1989Characteristic of study group: 208 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2622PDF: 815HTML: 5240 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1782PDF: 833HTML: 178 -
Mantle cell lymphoma relapsing at the lymphedematous arm.
1723PDF: 706HTML: 3805 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
4053PDF: 1498HTML: 8523 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2209PDF: 1622HTML: 319 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1809PDF: 1185HTML: 256







